{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T01:48:17Z","timestamp":1785721697085,"version":"3.56.0"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.pharmthera.2023.108521","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T20:41:47Z","timestamp":1693428107000},"page":"108521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Potential targeting of the tumor microenvironment to improve cancer virotherapy"],"prefix":"10.1016","volume":"250","author":[{"given":"Zi-Xian","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-hui","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiue-Cheng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Kempson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan-Chyr","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Ja","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2023.108521_bb0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ebiom.2018.04.020","article-title":"Lighting a fire in the tumor microenvironment using oncolytic immunotherapy","volume":"31","author":"Achard","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0010","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr. Biol."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0015","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1200\/JCO.20.03246","article-title":"Clinical responses of oncolytic Coxsackievirus A21 (V937) in patients with unresectable melanoma","volume":"39","author":"Andtbacka","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0020","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.cmet.2018.08.006","article-title":"Increased lactate secretion by Cancer cells sustains non-cell-autonomous adaptive resistance to MET and EGFR targeted therapies","volume":"28","author":"Apicella","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0025","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.ygyno.2020.02.034","article-title":"Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I\/II study are associated with an immunotherapeutic effect","volume":"157","author":"Arend","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.amsu.2022.104508","article-title":"Tumour microenvironment: Modulating effects, challenges, and future perspectives of oncolytic virotherapy in astrocytoma treatment","volume":"82","author":"Awuah","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0040","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0045","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0050","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature10358","article-title":"Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans","volume":"477","author":"Breitbach","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0055","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/sj.mt.6300215","article-title":"Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow","volume":"15","author":"Breitbach","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101454","article-title":"Lactate as a fulcrum of metabolism","volume":"35","author":"Brooks","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0065","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40001-016-0201-5","article-title":"Hyaluronidase: From clinical applications to molecular and cellular mechanisms","volume":"21","author":"Buhren","year":"2016","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0070","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1021\/acs.accounts.0c00518","article-title":"Tumor-targeted nanomedicine for immunotherapy","volume":"53","author":"Cabral","year":"2020","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0075","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1093\/jnci\/djt305","article-title":"Enhanced tumor uptake and penetration of virotherapy using polymer stealthing and focused ultrasound","volume":"105","author":"Carlisle","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0080","doi-asserted-by":"crossref","first-page":"11548","DOI":"10.1021\/acsnano.6b06182","article-title":"Oncolytic adenovirus complexes coated with lipids and calcium phosphate for Cancer gene therapy","volume":"10","author":"Chen","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0085","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1016\/j.biomaterials.2012.01.027","article-title":"Simultaneous gene transduction and silencing using stimuli-responsive viral\/nonviral chimeric nanoparticles","volume":"33","author":"Cho","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0090","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12951-022-01762-6","article-title":"Lactate oxidase\/catalase-displaying nanoparticles efficiently consume lactate in the tumor microenvironment to effectively suppress tumor growth","volume":"21","author":"Choi","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0095","doi-asserted-by":"crossref","first-page":"E354","DOI":"10.1152\/ajpendo.00111.2022","article-title":"Multimodal 3-D\/2-D human islet and duct imaging in exocrine and endocrine lesion environment: Associated pancreas tissue remodeling","volume":"323","author":"Chung","year":"2022","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0100","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature13490","article-title":"Functional polarization of tumour-associated macrophages by tumour-derived lactic acid","volume":"513","author":"Colegio","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0105","first-page":"3268","article-title":"Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma","volume":"6","author":"Cook","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0110","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004307","article-title":"OrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: A phase Ib study","volume":"10","author":"Cui","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0115","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3390\/cancers11040450","article-title":"Blockade of lactate dehydrogenase-A (LDH-A) improves efficacy of anti-programmed cell Death-1 (PD-1) therapy in melanoma","volume":"11","author":"Daneshmandi","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.lungcan.2020.10.007","article-title":"Oncolytic herpesvirus therapy for mesothelioma - A phase I\/IIa trial of intrapleural administration of HSV1716","volume":"150","author":"Danson","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0125","doi-asserted-by":"crossref","first-page":"2103470","DOI":"10.1002\/advs.202103470","article-title":"An inter-supplementary biohybrid system based on natural killer cells for the combinational immunotherapy and virotherapy of cancer","volume":"9","author":"Ding","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0130","doi-asserted-by":"crossref","first-page":"eaan4672","DOI":"10.1126\/science.aan4672","article-title":"Gene therapy comes of age","volume":"359","author":"Dunbar","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0135","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.omto.2019.12.003","article-title":"Generation of a tumor-specific chemokine gradient using oncolytic vesicular stomatitis virus encoding CXCL9","volume":"16","author":"Eckert","year":"2020","journal-title":"Mol. Ther. Oncolyt."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0140","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/0008-5472.CAN-12-1597","article-title":"Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy","volume":"73","author":"Eisenstein","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0145","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-019-0267-8","article-title":"Form and function for T cells in health and disease","volume":"20","author":"Farber","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0150","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S1470-2045(21)00245-X","article-title":"Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: A first-in-human, phase 1, dose-escalation trial","volume":"22","author":"Fares","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0155","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omto.2021.05.009","article-title":"Hyaluronidase expression within tumors increases virotherapy efficacy and T cell accumulation","volume":"22","author":"Farrera-Sal","year":"2021","journal-title":"Mol. Ther. Oncolyt."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0160","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.cell.2017.09.019","article-title":"Lactate metabolism in human lung tumors","volume":"171","author":"Faubert","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0165","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.15252\/emmm.201707567","article-title":"Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies","volume":"9","author":"Freedman","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0170","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","article-title":"Oncolytic HSV-1 G207 Immunovirotherapy for pediatric high-grade gliomas","volume":"384","author":"Friedman","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0175","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1056\/NEJMoa2202028","article-title":"Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma","volume":"386","author":"G\u00e1llego P\u00e9rez-Larraya","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0180","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1158\/1078-0432.CCR-07-4732","article-title":"Intratumoral Coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models","volume":"14","author":"Ganesh","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0185","doi-asserted-by":"crossref","first-page":"1904639","DOI":"10.1002\/adma.201904639","article-title":"Intra\/extracellular lactic acid exhaustion for synergistic metabolic therapy and immunotherapy of tumors","volume":"31","author":"Gao","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0190","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3390\/pharmaceutics13070949","article-title":"Polymer coated oncolytic adenovirus to selectively target hepatocellular carcinoma cells","volume":"13","author":"Garofalo","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0195","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.virol.2015.10.019","article-title":"Combined therapy of oncolytic adenovirus and temozolomide enhances lung cancer virotherapy in vitro and in vivo","volume":"487","author":"Gomez-Gutierrez","year":"2016","journal-title":"Virology"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0200","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1158\/1078-0432.CCR-22-2263","article-title":"A phase I dose-escalation study of AZD3965, an oral Monocarboxylate transporter 1 inhibitor, in patients with advanced cancer","volume":"29","author":"Halford","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0205","doi-asserted-by":"crossref","first-page":"eabg2752","DOI":"10.1126\/science.abg2752","article-title":"CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses","volume":"379","author":"He","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0210","doi-asserted-by":"crossref","first-page":"295","DOI":"10.7150\/thno.16192","article-title":"Targeting of magnetic nanoparticle-coated microbubbles to the vascular wall empowers site-specific lentiviral gene delivery in vivo","volume":"7","author":"Heun","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0215","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/978-3-030-34025-4_16","article-title":"The metabolic remodelling in lung cancer and its putative consequence in therapy response","volume":"1219","author":"Hipolito","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0220","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1186\/s12885-018-4453-z","article-title":"A phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer","volume":"18","author":"Hirooka","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0225","doi-asserted-by":"crossref","first-page":"8705","DOI":"10.1021\/acsnano.6b04155","article-title":"Viral\/nonviral chimeric nanoparticles to synergistically suppress leukemia proliferation via simultaneous gene transduction and silencing","volume":"10","author":"Hong","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0230","doi-asserted-by":"crossref","first-page":"24020","DOI":"10.1021\/acsomega.2c03213","article-title":"Macrophage distribution affected by virus-encoded granulocyte macrophage colony stimulating factor combined with lactate oxidase","volume":"7","author":"Hsieh","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0235","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","article-title":"Extracellular matrix and its therapeutic potential for cancer treatment","volume":"6","author":"Huang","year":"2021","journal-title":"Sign. Transd. Target. Ther."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0240","article-title":"Tumor-associated macrophages in multiple myeloma: Advances in biology and therapy","volume":"10","author":"Jennifer","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.matdes.2022.110961","article-title":"Cascades catalyzed lactic acid depletion coordinated with photothermal therapy for enhanced cancer immunotherapy","volume":"221","author":"Jz","year":"2022","journal-title":"Mater. Des."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0250","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.4049\/jimmunol.1700435","article-title":"Oncolytic Reovirus inhibits immunosuppressive activity of myeloid-derived suppressor cells in a TLR3-dependent manner","volume":"200","author":"Katayama","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0255","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1146\/annurev-virology-092818-015530","article-title":"Recombinant adeno-associated virus gene therapy in light of Luxturna (and Zolgensma and Glybera): Where are we, and how did we get here?","volume":"6","author":"Keeler","year":"2019","journal-title":"Ann. Rev. Virol."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0260","doi-asserted-by":"crossref","first-page":"2241710","DOI":"10.1080\/2162402X.2023.2241710","article-title":"Effective intravenous delivery of adenovirus armed with TNF\u03b1 and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer","volume":"12","author":"Kudling","year":"2023","journal-title":"OncoImmunology"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0265","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/d41573-021-00017-7","article-title":"The clinical landscape for AAV gene therapies","volume":"20","author":"Kuzmin","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0270","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1023\/B:CANC.0000031768.89246.d7","article-title":"Hypoxic gene expression and metastasis","volume":"23","author":"Le","year":"2004","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0275","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/526622a","article-title":"Cancer-fighting viruses win approval","volume":"526","author":"Ledford","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0280","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/PPO.0000000000000105","article-title":"Imaging tumor metabolism using positron emission tomography","volume":"21","author":"Lewis","year":"2015","journal-title":"Cancer J."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0285","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0290","article-title":"Nanomedicine for T-Cell mediated immunotherapy","author":"Li","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0295","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/PPO.0000000000000097","article-title":"Imaging tumor metabolism using in vivo magnetic resonance spectroscopy","volume":"21","author":"Li","year":"2015","journal-title":"Cancer J."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0300","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1021\/acs.bioconjchem.9b00618","article-title":"Repolarization of M2 to M1 macrophages triggered by lactate oxidase released from methylcellulose hydrogel","volume":"30","author":"Liao","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0305","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jconrel.2020.05.043","article-title":"Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer","volume":"324","author":"Liao","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0310","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/cnma.201700251","article-title":"Micro-scale RNA interference using iron oxide nanoparticle-modified lentivirus","volume":"4","author":"Liao","year":"2018","journal-title":"ChemNanoMat"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0315","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1016\/j.drudis.2021.07.014","article-title":"Potential therapeutics using tumor-secreted lactate in nonsmall cell lung cancer","volume":"26","author":"Liao","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0320","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: Basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Sign. Transd. Target. Ther."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0325","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.7150\/thno.83495","article-title":"OX40L-armed oncolytic virus boosts T-cell response and remodels tumor microenvironment for pancreatic Cancer treatment","volume":"13","author":"Liu","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0330","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/1078-0432.CCR-19-2078","article-title":"Pembrolizumab in combination with the oncolytic virus Pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma: A phase Ib study","volume":"26","author":"Mahalingam","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0335","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2021.10.069","article-title":"A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer","volume":"163","author":"Manyam","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0340","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cytogfr.2020.06.005","article-title":"The two-faces of NK cells in oncolytic virotherapy","volume":"56","author":"Marotel","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0345","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jconrel.2014.08.020","article-title":"Enhanced gene delivery in porcine vasculature tissue following incorporation of adeno-associated virus nanoparticles into porous silicon microparticles","volume":"194","author":"McConnell","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0350","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","article-title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","volume":"18","author":"Melero","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0355","article-title":"Evolving role of oncolytic Virotherapy: Challenges and prospects in clinical practice","volume":"5","author":"Moaven","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0360","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.biomaterials.2014.11.021","article-title":"Dual tumor targeting with pH-sensitive and bioreducible polymer-complexed oncolytic adenovirus","volume":"41","author":"Moon","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0365","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/d41573-023-00103-y","article-title":"FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0370","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001800","article-title":"Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy","volume":"9","author":"Mu\u00f1oz","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0375","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jconrel.2019.04.040","article-title":"Systemic administration of human mesenchymal stromal cells infected with polymer-coated oncolytic adenovirus induces efficient pancreatic tumor homing and infiltration","volume":"305","author":"Na","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0380","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: A phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0385","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1158\/2767-9764.CRC-23-0145","article-title":"A pilot study of neoadjuvant nivolumab, ipilimumab and intralesional oncolytic virotherapy for HER2-negative breast cancer","volume":"3","author":"Nguyen","year":"2023","journal-title":"Cancer Res. (Communications)"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0390","doi-asserted-by":"crossref","first-page":"16022","DOI":"10.1038\/mto.2016.22","article-title":"A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity","volume":"3","author":"Nosaki","year":"2016","journal-title":"Mol. Ther. Oncolyt."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0395","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.cmet.2018.09.004","article-title":"Emerging technologies to image tissue metabolism","volume":"29","author":"Ntziachristos","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0400","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13014-020-01593-5","article-title":"A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR)","volume":"15","author":"O\u2019Cathail","year":"2020","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0405","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1158\/1078-0432.CCR-21-2347","article-title":"NOTCH-induced MDSC recruitment after oHSV Virotherapy in CNS cancer models modulates antitumor immunotherapy","volume":"28","author":"Otani","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0410","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1158\/1078-0432.CCR-15-2709","article-title":"Talimogene Laherparepvec for the treatment of advanced melanoma","volume":"22","author":"Ott","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0415","doi-asserted-by":"crossref","first-page":"2100048","DOI":"10.1002\/adtp.202100048","article-title":"Enhanced targeting and immune activation of tumor microenvironment by nanomodified anti-PD1 in liver cancer","volume":"4","author":"Ou","year":"2021","journal-title":"Adv. Therap."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0420","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1038\/s41375-020-0828-7","article-title":"Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma","volume":"34","author":"Packiriswamy","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0425","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/0008-5472.CAN-17-0764","article-title":"Monocarboxylate transporter MCT1 promotes tumor metastasis independently of its activity as a lactate transporter","volume":"77","author":"Payen","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0430","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.ymthe.2020.02.016","article-title":"Oncolytic adenovirus armed with BiTE, cytokine, and checkpoint inhibitor enables CAR T cells to control the growth of heterogeneous tumors","volume":"28","author":"Porter","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0435","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-21-3324","article-title":"Convection enhanced delivery of the oncolytic adenovirus Delta24-RGD in patients with recurrent GBM: A Phase I clinical trial including correlative studies","volume":"28","author":"van Putten","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0440","article-title":"Polymer-coated viral vectors: Hybrid nanosystems for gene therapy","volume":"20","author":"Rajagopal","year":"2018","journal-title":"J. Genet. Med."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0445","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41586-021-03442-1","article-title":"Cell-programmed nutrient partitioning in the tumour microenvironment","volume":"593","author":"Reinfeld","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0450","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41417-021-00359-9","article-title":"Combination therapy with CAR T cells and oncolytic viruses: A new era in cancer immunotherapy","volume":"29","author":"Rezaei","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0455","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/mt.2015.15","article-title":"BRAF- and MEK-targeted small molecule inhibitors exert enhanced Antimelanoma effects in combination with oncolytic Reovirus through ER stress","volume":"23","author":"Roulstone","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0460","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ymthe.2020.01.019","article-title":"First-in-human, first-in-child trial of autologous MSCs carrying the oncolytic virus Icovir-5 in patients with advanced tumors","volume":"28","author":"Ruano","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0465","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.mayocp.2014.04.003","article-title":"Remission of disseminated cancer after systemic oncolytic virotherapy","volume":"89","author":"Russell","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0470","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ccell.2017.07.006","article-title":"Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade","volume":"32","author":"Saha","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0475","doi-asserted-by":"crossref","first-page":"11877","DOI":"10.1128\/JVI.01717-12","article-title":"Evidence for pH-dependent protease activity in the adeno-associated virus capsid","volume":"86","author":"Salganik","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0480","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: Progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0485","doi-asserted-by":"crossref","first-page":"1900215","DOI":"10.1002\/adtp.201900215","article-title":"Clinical translation of nanomedicine and biomaterials for cancer immunotherapy: Progress and perspectives","volume":"3","author":"Shi","year":"2020","journal-title":"Adv. Therap."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0490","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0495","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1158\/1078-0432.CCR-20-3105","article-title":"A phase I trial of Talimogene Laherparepvec in combination with neoadjuvant chemotherapy for the treatment of nonmetastatic triple-negative breast cancer","volume":"27","author":"Soliman","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0500","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41591-023-02309-4","article-title":"Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: A phase 2 trial","volume":"29","author":"Soliman","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0505","doi-asserted-by":"crossref","first-page":"7149","DOI":"10.1038\/s41467-022-34791-8","article-title":"Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity","volume":"13","author":"Svensson-Arvelund","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0510","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/CCO.0000000000000108","article-title":"Antibody drug conjugates","volume":"26","author":"Teicher","year":"2014","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0515","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2174\/1568009622666220224110538","article-title":"Antibody-drug conjugate targets, drugs, and linkers","volume":"22","author":"Teicher","year":"2022","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0520","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody\u2013drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0525","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1038\/s41467-022-31262-y","article-title":"A phase I\/II study of triple-mutated oncolytic herpes virus G47\u2206 in patients with progressive glioblastoma","volume":"13","author":"Todo","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0530","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: A phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0535","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13045-022-01370-9","article-title":"Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma","volume":"15","author":"Toulmonde","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0540","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1021\/mp100123t","article-title":"Boosting oncolytic adenovirus potency with magnetic nanoparticles and magnetic force","volume":"7","author":"Tresilwised","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0545","doi-asserted-by":"crossref","first-page":"10339","DOI":"10.1021\/acsnano.6b06051","article-title":"Remote control of light-triggered virotherapy","volume":"10","author":"Tseng","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0550","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.1021\/acsnano.8b02813","article-title":"Targeting tumor microenvironment by bioreduction-activated nanoparticles for light-triggered virotherapy","volume":"12","author":"Tseng","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2022.101582","article-title":"An acid degradable, lactate oxidizing nanoparticle formulation for non-small cell lung cancer virotherapy","volume":"46","author":"Tseng","year":"2022","journal-title":"Nano Today"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0560","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jconrel.2013.05.009","article-title":"Environment acidity triggers release of recombinant adeno-associated virus serotype 2 from a tunable matrix","volume":"170","author":"Tseng","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0565","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.1038\/ncomms7456","article-title":"Highly specific in vivo gene delivery for p53-mediated apoptosis and genetic photodynamic therapies of tumour","volume":"6","author":"Tseng","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0570","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0575","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0580","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ymthe.2022.08.021","article-title":"CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0585","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004167","article-title":"Remodeling the tumor microenvironment by oncolytic viruses: Beyond oncolysis of tumor cells for cancer treatment","volume":"10","author":"Wang","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0590","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1038\/s41467-023-39683-z","article-title":"Oncolytic viruses engineered to enforce cholesterol efflux restore tumor-associated macrophage phagocytosis and anti-tumor immunity in glioblastoma","volume":"14","author":"Wang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0595","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1021\/acs.molpharmaceut.8b01046","article-title":"Liposome encapsulation of oncolytic virus M1 to reduce immunogenicity and immune clearance in vivo","volume":"16","author":"Wang","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0600","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1089\/humc.2017.002","article-title":"Rationale and design of a Phase 1 clinical trial to evaluate HSV G207 alone or with a single radiation dose in children with progressive or recurrent malignant Supratentorial brain tumors","volume":"28","author":"Waters","year":"2017","journal-title":"Human Gene Ther. Clin. Dev."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0605","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41586-020-03045-2","article-title":"Metabolic support of tumour-infiltrating regulatory T cells by lactic acid","volume":"591","author":"Watson","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0610","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","article-title":"Targeting tumor-associated macrophages to synergize tumor immunotherapy","volume":"6","author":"Xiang","year":"2021","journal-title":"Sign. Transd. Target. Ther."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0615","article-title":"Oncolytic adenovirus-loaded magnetic-driven Janus tumor cell robots for active and targeted virotherapy of homologous carcinoma","volume":"30","author":"Xie","year":"2023","journal-title":"Mater. Today Chem."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0620","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1038\/s41467-021-26003-6","article-title":"An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma","volume":"12","author":"Xu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0625","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-020-0843-1","article-title":"Myeloid-derived suppressor cells\u2014New and exciting players in lung cancer","volume":"13","author":"Yang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0630","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.copbio.2019.11.016","article-title":"Design and application of oncolytic viruses for cancer immunotherapy","volume":"65","author":"Ylosmaki","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0635","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1172\/JCI98047","article-title":"PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy","volume":"128","author":"Zamarin","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0640","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/s41586-021-03326-4","article-title":"CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours","volume":"591","author":"Zappasodi","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0645","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12943-020-01275-6","article-title":"Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0650","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.cmet.2020.05.004","article-title":"Endothelial lactate controls muscle regeneration from ischemia by inducing M2-like macrophage polarization","volume":"31","author":"Zhang","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.pharmthera.2023.108521_bb0655","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.drudis.2018.05.014","article-title":"Targeting cancer metabolism to develop human lactate dehydrogenase (hLDH)5 inhibitors","volume":"23","author":"Zhang","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0660","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cell.2019.05.003","article-title":"Lactate is a natural suppressor of RLR signaling by targeting MAVS","volume":"178","author":"Zhang","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0665","doi-asserted-by":"crossref","first-page":"16934","DOI":"10.1021\/acsnano.1c08026","article-title":"Metal-phenolic network-enabled lactic acid consumption reverses immunosuppressive tumor microenvironment for Sonodynamic therapy","volume":"15","author":"Zhang","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.pharmthera.2023.108521_bb0670","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41420-023-01356-7","article-title":"Targeting tumor-associated macrophages in hepatocellular carcinoma: Biology, strategy, and immunotherapy","volume":"9","author":"Zheng","year":"2023","journal-title":"Cell Death Dis."}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823001857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823001857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:35:33Z","timestamp":1759012533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725823001857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":133,"alternative-id":["S0163725823001857"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108521","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential targeting of the tumor microenvironment to improve cancer virotherapy","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108521","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108521"}}